AstraZeneca reported second-quarter revenue of $14.46 billion, surpassing analysts’ consensus of $14.12 billion and setting a company record. Core earnings were $2.17 a share, matching expectations, while the core operating margin held at 32%. Sales from oncology medicines jumped 18% to $6.31 billion, led by flagship drugs Tagrisso and Imfinzi, the latter generating $1.46 billion versus forecasts of $1.34 billion. Newer treatments for heart and kidney disease also contributed, offsetting weaker demand for the older cardiovascular drug Brilinta, which is facing generic competition. Management reaffirmed guidance for 2025, projecting high single-digit percentage growth in total revenue and low double-digit growth in core EPS at constant exchange rates. The interim dividend was raised 3% to $1.03 per share. The company highlighted its plan to invest $50 billion in US manufacturing and research by 2030, a move intended to mitigate potential tariff risks and underpin a goal of $80 billion in annual revenue by the end of the decade. AstraZeneca shares climbed about 3% on the results.